ALKBH1 contributes to renal cell carcinoma progression by reducing N6‐methyladenine of GPR137

Author:

Li Lin12,Zhu Chongying3,Xu Qiang1,Xu Shouying1,Ye Jianqing4,Xu Da2,Wang Lei2,Gan Sishun2,Liu Bing2,Tang Chao1ORCID

Affiliation:

1. National Clinical Research Center for Child Health of the Children's Hospital Zhejiang University School of Medicine Hangzhou 310052 China

2. Department of Urology Third Affiliated Hospital of the Second Military Medical University Shanghai 201805 China

3. The Department of Obstetrics and Gynecology Ruijin Hospital, Shanghai Jiaotong University School of Medicine 197 Ruijin 2nd Road, Huangpu District Shanghai 200025 China

4. Department of Urology Xinhua Hospital, Shanghai Jiaotong University, School of Medicine 1665 Kongjiang Road Shanghai 200092 China

Abstract

AbstractBackgroundRenal cell carcinoma (RCC) accounts for approximately 4% of all adult malignancies with high mortality worldwide. Although conventional chemotherapy and radiotherapy treatment has been applied for RCC in clinic, the mortality rate of patients is increasing each year, and patients with metastatic RCC are still suffering from poor prognosis. Thus, further investigation of the molecular mechanisms responsible for the development and progression of RCC is of particular importance.MethodsTotal of 10 pairs of RCC tissues and adjacent nontumor tissues were collected for examination of ALKBH1 and GPR137 expression. The correlations between ALKBH1 and GPR137 expression in RCC patient were assessed by GEPIA online tool and were analyzed using auto best cutoff. The human RCC cell lines Caki‐1, 786‐O, ACHN, Osrc2, A498, and 769‐P, were used for mechanistic investigation.ResultsHere, we report that the expression of AlkB homologue 1 (ALKBH1) is upregulated in RCC tissues, which is correlated with G‐protein‐coupled receptor 137 (GPR137) expression. The elevated expression of ALKBH1 is associated with RCC cell malignant characteristics, including cell proliferation and movement (migration and invasion). Mechanistic investigation further reveals that ALKBH1 reduces m6A levels of GPR137 mRNA in RCC cells, which upregulates GPR137 mRNA levels, resulting in the increased GPR137 protein expression subsequently and the enhanced RCC cell biological actions consequently. In contrast, the suppression of GPR137 effectively alleviates the ALKBH1‐induced malignancies of RCC cells.ConclusionOur results indicate that ALKBH1–GPR137 axis might be used as a potential therapeutic target in RCC, contributing to finding new prognostic biomarkers for RCC at an early stage.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Shanghai

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3